First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial



Summary

A phase 2 trial investigated sacituzumab tirumotecan combined with tagitanlimab as a first-line treatment for advanced non-small-cell lung cancer (NSCLC). The study aimed to assess the efficacy and safety of this novel combination therapy. The findings will provide valuable insights into the potential of this regimen for improving outcomes in patients with advanced NSCLC who have not previously received systemic therapy. This research is crucial in exploring new treatment options and potentially advancing the standard of care for this challenging disease. Full study details and results are needed to determine the actual clinical impact.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!